Logo

Lilly Collaborates with Rigel to Develop RIPK1 Inhibitors for Immunological and Neurodegenerative Diseases

Share this

Lilly Collaborates with Rigel to Develop RIPK1 Inhibitors for Immunological and Neurodegenerative Diseases

Shots:

  • Rigel to receive $125M up front and is also eligible to receive ~$835M as development- regulatory and commercial milestones as well as royalties- which will vary depending upon Rigel's clinical development investment
  • Lilly to get an exclusive WW license to Rigel's RIPK1 inhibitors- including its R552 in all indications. The companies will co-develop R552 at specified contribution levels under which Lilly will be responsible for all costs of global commercialization & Rigel gets the right to co-commercialize R552 in the US
  • Rigel will initiate P-II trials of R552 in 2021. Pursuant to the collaboration- Lilly will solely lead all clinical development of RIPK1 inhibitors in CNS diseases

 ­ Ref: PRNewswire | Image: ABC News

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions